Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement shield the heart from reperfusion injury?

NCT ID NCT06564909

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial tests whether L-carnitine, a natural compound, can reduce the damage that occurs when blood flow is restored to the heart after a heart attack. Researchers will give L-carnitine to patients with ST-elevation myocardial infarction (STEMI) who undergo angioplasty, and measure blood markers of oxidative stress and fibrosis. The goal is to see if L-carnitine can protect heart muscle and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
L-carnitine given intravenously and orally alongside standard heart attack care
What this could lead to
If it works, L-carnitine could become a simple add-on treatment to limit heart muscle damage after a heart attack, potentially improving recovery and reducing long-term heart failure risk.
What could go wrong
This is a small Phase 2 trial, so results may not hold up in larger studies. L-carnitine may not reduce injury markers, and side effects or interactions with standard care are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 76 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female or male aged \>18 and \< 75 years. * STEMI patients undergoing PCI. Exclusion Criteria: * Patients with a recent history of myocardial infarction (MI), a previous PCI, a previous coronary artery bypass graft, or any cardiac surgery. * A late presentation (\>12 h), unsuccessful primary PCI (residual stenosis \>50% in the culprit lesion after procedure), * Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI, * Concurrent Infectious or active inflammatory disease, * Severe liver or renal disease, (aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 3x ULN or Total bilirubin \> 3 x ULN), (CrCl \< 60 ml/min (based on the Cockroft-Gault equation) * Neoplasm, or hematological disorders * Pregnant or breast-feeding patients * Active participation in another clinical study * Patients taking antioxidant drugs. * History of or known allergy or intolerability to the study medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemia reperfusion injury myocardial infarction Myocardial Reperfusion Injury ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction Reperfusion injury, myocardial

Contacts and locations

Locations

  • Ain Shams University Hospitals

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.